ADVENT On Air

ADVENT Program
  • 4.7 (14)
  • Medicine
  • Updated Monthly

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025

  1. 7h ago

    ADVENT AD Podcast: Atopic Dermatitis: Understanding Bone Health & Growth in Pediatric Atopic Dermatitis

    In this episode, Dr. Amy Paller and Dr. Lisa Swanson as they delve into the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth observed with advanced therapy, especially among children with shorter stature at baseline.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   ·       Disclaimer: o   This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. o   The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. o   The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. ·       Speaker disclosures: o   Lisa Swanson, MD, FAAD, has served as an investigator for Arcutis, Castle, Organon, and Sun. Dr. Swanson has participated as a speaker for AbbVie, Arcutis, Galderma, Incyte, Johnson & Johnson, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, and Verrica. In addition, she has served as a consultant and advisory board member for AbbVie, Almirall, Alphyn, Arcutis, Boehringer Ingelheim, Castle, Chiesi, Galderma, Incyte, Johnson & Johnson, Leo, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, and Verrica. o   Amy Paller, MD, MS, has served as an advisor and consultant and has received grant funding from AbbVie, Abeona, Aegerion Pharmaceuticals, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek Biosciences, Catawba, Eli Lilly and Company, Galderma, Gilead, InMed Pharmaceuticals, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy (consultant with honorarium), TWi Biotechnology, and UCB. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2600170 – 1.0 – 07/2026    Course Descriptors:  MAT-GLB-2604085 – 1.0 – 07/2026

  2. 7h ago

    ADVENT AD Podcast: Atopic Dermatitis: Understanding Bone Health & Growth in Pediatric Atopic Dermatitis

    In this episode, Dr. Amy Paller and Dr. Lisa Swanson as they delve into the risk of low bone mineral density and impaired growth observed in pediatric atopic dermatitis.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   ·       Disclaimer: o   This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. o   The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. o   The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. ·       Speaker disclosures: o   Lisa Swanson, MD, FAAD, has served as an investigator for Arcutis, Castle, Organon, and Sun. Dr. Swanson has participated as a speaker for AbbVie, Arcutis, Galderma, Incyte, Johnson & Johnson, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, and Verrica. In addition, she has served as a consultant and advisory board member for AbbVie, Almirall, Alphyn, Arcutis, Boehringer Ingelheim, Castle, Chiesi, Galderma, Incyte, Johnson & Johnson, Leo, Lilly, Organon, Pelthos, Pfizer, Sanofi-Regeneron, and Verrica. o   Amy Paller, MD, MS, has served as an advisor and consultant and has received grant funding from AbbVie, Abeona, Aegerion Pharmaceuticals, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek Biosciences, Catawba, Eli Lilly and Company, Galderma, Gilead, InMed Pharmaceuticals, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy (consultant with honorarium), TWi Biotechnology, and UCB. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.   MAT-US-2603864 v1.0 - P Expiration Date: 07/24/2028    Course Descriptors:  MAT-US-2608354 V1.0 – P Expiration Date: 07/24/2028

  3. Jun 8

    More Than Just Difficulty Swallowing: Disease Burden and Diagnosis of EoE

    Dr. Joshua Wechsler and Prof. Arjan Bredenoord discuss the burden of disease in patients with EoE, the impact on quality of life, and how to overcome challenges in identifying EoE. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Arjan Bredenoord, MD, PhD (Adult Gastroenterologist): Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands Joshua Wechsler, MD, MSci (Pediatric Gastroenterologist): Attending Physician, Division of Gastroenterology, Hepatology & Nutrition; Campaign Urging Research for Eosinophilic Disorders (CURED) Foundation Research Scholar; Medical Director, Eosinophilic Gastrointestinal Disorders Program; Assistant Professor in Pediatrics & Medicine, Northwestern University – The Feinberg School of Medicine © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304791 - 2.0 - 05/2026 MAT-US-2404998 v2.0 - P Expiration Date: 05/21/2028

  4. May 7

    The Multifaceted Patient Burden and Drivers of Disease in Prurigo Nodularis

    In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Sarina Elmariah, MD, PhD, MPH has the following interests to disclose: Consultant, advisor, or investigator: Bambusa Therapeutics, Celldex, Disc Medicine, Galderma, Incyte, Novartis, Pfizer, Regeneron, Sanofi, ZenZema Brian Kim, MD, is co-founder of Alys Pharmaceuticals and Neurommune Therapeutics; he has served as a consultant for ABRAX Japan, AbbVie, Amgen, Attovia Therapeutics, Eli Lilly and Company, Evommune, Galderma, Gilead, LEO Pharma, Neurocrine, Novartis, Pfizer, Recens Medical, Regeneron, Sanofi, Septerna, Triveni Bio; he has stock in ABRAX Japan, Alys Pharamaceuticals, Attovia Therapeutics, Locus Biosciences, Neurommune Therapeutics, Recens Medical, and Triveni Bio.  © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2504334 – 1.0 – 05/2026 MAT-US-2604824 v1.0 - P Expiration Date: 05/4/2028

  5. May 6

    Breaking the Cycle: The OCS Burden in CRSwNP

    Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Luong: Served on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron; Consultant to Maxwell Biosciences, Medtronic and Stryker; Grant funding from Eli Lily and Sanofi. Cornet: Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Mylan, Stallergenes Greer and Medtronic. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2601160- 1.0 - 04/2026

  6. Mar 25

    Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

    Dr. Ikuo Hirano and Dr. Margaret (Peggy) Marcon highlight why dysphagia may be overlooked and share insights from their own clinical practice on how to unmask EoE behind patients' adaptive behaviors. Please note that this podcast was recorded prior to the passing of Dr. Hirano. His expertise and contributions to the field are honored and remembered with deep respect. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only.   Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr. Ikuo Hirano, MD has received consultation fees from Adare/Ellodi, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calypso, Regeneron, Sanofi, Shire/Takeda, Phathom, Nexstone. He has participated in clinical trials for AstraZeneca, Celgene/BMS, Regeneron, Shire/Takeda, Ellodi/Adare, Allakos and been a member of Speaker Bureaus for Sanofi and Regeneron. Dr. Peggy Marcon has received fees from Nutricia, Sanofi for education. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304790 - 2.0 - 03/2026 MAT-US-2402674 v3.0 - P Expiration Date: 03/09/2028

  7. Jan 30

    Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

    Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Simon Couillard: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Association Pulmonaire du Québec, the Academy of Medical Sciences, AstraZeneca, bioMérieux, Circassia Niox Group, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec’s Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Circassia Niox Group and Valeo Pharma; he received consultancy fees for FirstThought, Apogee Therapeutics, Upstream Bio, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and detains stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry); he is co-inventor for the patent filed as ‘Method for alleviating dyspnea with neuromodulation’. He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners as well as therapeutic indications for Enerzair, and is a member of the asthma steering committee of the Canadian Thoracic Society, 2025-05-26 Dr. Sharon Dell: Grants and Research Support: Boehringer Ingelheim, Merck, Parion Sciences, Sanofi, VertexPharmaceuticals; Honoraria or Consultation Fees: AstraZeneca, Novartis, Regeneron Pharmaceuticals Inc., Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2506512 - 1.0 - 01/2026 MAT-US-2600428 v1.0 - P Expiration Date: 01/16/2028

  8. Jan 30

    Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

    Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503097 - 1.0 - 01/2026 MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028

See All (28)

Ratings & Reviews

4.7
out of 5
14 Ratings

About

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field. The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area. Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com. This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals. ©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2302644 v2.0 07/2023 MAT-US-2304947 v1.0-P Exp. Date 07/07/2025

Information

  • Creator
    ADVENT Program
  • Years Active
    2023 - 2026
  • Episodes
    28
  • Rating
    Clean
  • Show Website
    ADVENT On Air